In a report released on March 11, Steven Valiquette from Mizuho Securities maintained a Hold rating on LifeMD (LFMD – Research Report). The ...
H.C. Wainwright analyst Yi Chen raised the firm’s price target on LifeMD (LFMD) to $14 from $12 and keeps a Buy rating on the shares. The ...
(Reuters) -Telehealth firms Teladoc and LifeMD said on Thursday they had signed an agreement with Gifthealth, the pharmacy ...
Telehealth firms Teladoc and LifeMD said on Thursday they had signed an agreement to offer Eli Lilly's weight-loss drug ...
LifeMD reported a fourth-quarter loss per share of 2 cents. Analysts were expecting a loss of 5 cents per share, according to FactSet. Revenue for the fourth quarter came in at $64.3 million. Analysts ...
LifeMD, a virtual primary care services provider, said it is integrating with Gifthealth which will make Lilly's single-dose vials of Zepbound accessible to the company's eligible patients.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results